MedTrace Logo

Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04373395 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2020-09-16

No results posted yet for this study

Summary

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Conditions

Interventions

PROCEDURE

D-CLAG

Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • First People's Hospital of Hangzhou

    collaborator OTHER

  • Zhejiang Provincial Tongde Hospital

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • The Sixth Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    collaborator INDUSTRY

  • Hanhui Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04373395 on ClinicalTrials.gov